663 Phase 2 multi-cohort clinical study evaluating disitamab vedotin alone and in combination with pembrolizumab in patients with HER2-expressing unresectable or metastatic urothelial carcinoma (RC48G001, trial in progress)

Autor:	Matthew Galsky, Peter O’Donnell, Earle Burgess, Michiel Van der Heijden, Laurence Krieger, Andrea Necchi, Evan Yu, Nobuaki Matsubara, Matthew Campbell, Saikrishna Gadde, Jeanny Aragon-Ching, Vadim Koshkin, Wei Zhang, Kevin Sokolowski, Thomas Powles
Rok vydání:	2022
Zdroj:	Regular and Young Investigator Award Abstracts.
DOI:	10.1136/jitc-2022-sitc2022.0663
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::55fdec1a80488fe5f60dbc94b50b62f4 https://doi.org/10.1136/jitc-2022-sitc2022.0663 Zobrazit plný text záznamu